BeyondSpring (BYSI) vs Context Therapeutics (CNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BeyondSpring (BYSI) has outperformed Context Therapeutics (CNTX) over the past year, losing 82.8% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -97.7% for BYSI. Context Therapeutics is the larger company by market cap ($14.7 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BYSI | CNTX |
|---|---|---|
| Share price | $0.33 | $0.16 |
| Market cap | $13.66M | $14.70M |
| 1-day change | -24.49% | -5.10% |
| YTD return | -79.75% | -89.12% |
| 1-year return | -82.77% | -85.32% |
| 5-year return | -97.70% | -96.86% |
| EPS (TTM) | $-0.20 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-1.01M | $-36.12M |
| 52-week high | $2.44 | $3.62 |
| 52-week low | $0.299 | $0.153 |
| Distance from 52-week high | -86.48% | -95.58% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2418.75% |
| Average volume | 261.79K | 1.42M |
| Shares outstanding | 41.41M | 91.88M |
| Employees | 44 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
BYSI vs CNTX FAQ
Which is bigger, BeyondSpring or Context Therapeutics?
Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $13.66M for BeyondSpring (BYSI).
Which stock has performed better over the past year, BYSI or CNTX?
BYSI returned -82.77% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are BeyondSpring and Context Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.